
Wockhardt's Q2 FY27 revenue surged 23.9% to ₹969 crore from ₹782 crore in the year-ago period, driven by strong performance across multiple segments. According to reports from CNBC TV18, the company's biotech operations recorded revenue of ₹252 crore in Q2 FY27, registering 68% growth year on year. For the first half of FY27, the biotech segment's revenue rose 87% to ₹487 crore, with emerging-markets biotech business growing around 110% in H1 FY27. The company attributed this growth to new business opportunities and partnerships in markets including Brazil, Thailand, Egypt, Algeria and Latin America.
Despite strong revenue growth, consolidated net profit fell 11% to ₹180 crore for the first half of FY27, compared with a loss of ₹26 crore in the year-ago period. As reported by Moneycontrol, the company reported a net loss of ₹45 crore in Q2 FY27 due to Zaynich pre-launch expenses. EBITDA increased 35% to ₹353 crore from ₹261 crore for H1 FY27, while operating margin improved to 18.6% from 17.2%. The margin compression was attributed to higher operating costs that offset the benefits of strong revenue growth across key business segments, with the company noting that first-half EBITDA stood at ₹398 crore after excluding ₹45 crore in Zaynich pre-launch expenses.
The emerging-markets business recorded revenue of ₹310 crore in Q2, an increase of 52% year on year, with H1 revenue rising 54% to ₹574 crore. According to Moneycontrol, growth was driven mainly by the biotech insulin segment and traction from Latin American operations. The India branded business reported revenue of ₹146 crore in Q2, up 8% year on year, with H1 revenue rising 14% to ₹303 crore, attributed to diabetes therapy portfolio and NCE EMROK launches. In the UK, revenue stood at GBP 28 million in the September quarter, up 4% year on year. The company also reported 24 international product filings, 18 approvals and 11 launches, alongside two biosimilar filings and four approvals.
For the first half of FY27, Wockhardt reported revenue increase of 25% to ₹1,898 crore from ₹1,520 crore. As reported by Moneycontrol, first-half EBITDA increased 35% to ₹353 crore from ₹261 crore. The company noted that H1 EBITDA stood at ₹398 crore after excluding expenses incurred ahead of the launch of Zaynich. Shares of Wockhardt closed 0.32% lower at ₹1,895 on the NSE on Monday, ahead of the company's September-quarter earnings announcement. The company also filed seven patents and received six patent grants during the September quarter, taking its cumulative patent filings to 3,298 and patents held to 865.